Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.  

CME information and select publications here.